Massachusetts Eye & Ear Infirmary
Latest From Massachusetts Eye & Ear Infirmary
While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in November and December 2016.
Adopting an established endoscopic nasal grafting technique, researchers at Mass Eye and Ear have shown the ability to deliver a drug across the blood-brain barrier effectively and with reduced side effects. Their work could move rapidly into clinical testing in neurodegenerative diseases and could form the basis for delivering a wide range of existing drugs as well as new compounds whose development is predicated on use of the technique.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.